Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe Renews Innovative Medicines Initiative, With Funding Boost

This article was originally published in The Pink Sheet Daily

Executive Summary

With a new budget of €3.4 billion over the next seven years, Europe’s public-private partnership in health aims to tackle difficult-to-treat neurodegenerative diseases and new antibiotics.

You may also be interested in...

EU ADR App To Underpin Region’s Regulatory Approach To Social Media

EU regulators are set to launch an adverse drug reaction reporting app in March and will follow this up with a social media monitoring drive to improve pharmacovigilance.

On Visit To Japan, Sanofi’s Viehbacher Weighs In On Innovation Models, Clinical Trial Transparency

Increased funding and public-private interaction in a new research “control tower” would be welcomed by industry in Japan, Viehbacher said. But the CEO told PharmAsia News that he opposes expanded regulatory oversight on clinical trial transparency.

In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines

With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts